trifarotene: Clinical Trials

14 trials of trifarotene, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 1 active not recruiting, 1 terminated. 6 Phase 3, 3 Phase 1, 3 Phase 4, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 36Completed 5, Active not recruiting 1
Phase 13Completed 3
Phase 43Completed 3
Phase 22Completed 1, Terminated 1

Follow trifarotene: new trials by email Literature Review of trifarotene trials Research Report on trifarotene

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
Trifarotene, Vehicle Cream - Acne Vulgaris
Phase 3Active not recruitingGalderma R&D5612025-09-232026-08-24
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT - Acne Vulgaris
Phase 1CompletedSun Pharmaceutical Industries, Inc.10002024-06-202024-12-13
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
Trifarotene Cream 0.005%, Placebo, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories) - Acne Vulgaris
Phase 1CompletedSun Pharmaceutical Industries, Inc.7622023-02-222023-10-02
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo - Acne Vulgaris
Phase 3CompletedTeva Pharmaceuticals USA8072022-09-192024-09-26
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Trifarotene Cream, Trifarotene Vehicle Cream - Acne Vulgaris
Phase 4CompletedGalderma R&D1232021-12-222023-12-20
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
Trifarotene Cream, Trifarotene Vehicle Cream - Acne Vulgaris
Phase 4CompletedGalderma R&D1212021-05-282024-06-11
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle - Acne Vulgaris
Phase 4CompletedGalderma R&D2022020-07-292022-05-10
A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle - Lamellar Ichthyosis
Phase 2TerminatedMayne Pharma International Pty Ltd652019-05-012023-08-14
Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
Trifarotene - Acne Vulgaris
Phase 3CompletedGalderma R&D472019-03-272021-12-15
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
CD5789 (trifarotene) 50μg/g cream, Placebo cream - Acne Vulgaris
Phase 3CompletedGalderma R&D12082015-11-302019-11-12
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
CD5789 (trifarotene) 50µg/g Cream, Placebo Cream - Acne Vulgaris
Phase 3CompletedGalderma R&D12122015-11-012019-11-12
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
CD5789 (trifarotene) - Acne Vulgaris
Phase 3CompletedGalderma R&D4532015-02-232019-11-14
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)
CD5789 0.01% Cream - Lymphoma
Phase 1CompletedM.D. Anderson Cancer Center112013-02-012016-04-13
Dose Range Study of CD5789 in Acne Vulgaris
CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream - Acne Vulgaris
Phase 2CompletedGalderma R&D3042012-06-202021-09-20

Conditions studied

Acne Vulgaris (12)  ·  Facies (1)  ·  Ichthyosis, Lamellar (1)  ·  Lymphoma (1)

Sponsors

Galderma R&D (9)  ·  Sun Pharmaceutical Industries, Inc. (2)  ·  M.D. Anderson Cancer Center (1)  ·  Mayne Pharma International Pty Ltd (1)  ·  Teva Pharmaceuticals USA (1)

Countries

United States (13)  ·  Canada (3)  ·  Germany (3)  ·  Hungary (3)  ·  Spain (3)  ·  Czechia (2)  ·  France (2)  ·  Puerto Rico (2)  ·  Ukraine (2)  ·  Australia (1)  ·  China (1)  ·  Israel (1)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)

Top investigators

Kevin Chan (2)  ·  Natalie Yantovskiy (2)  ·  Jerry Tan, MD (1)  ·  Keith A. Choate, MD (1)  ·  Madeleine Duvic, MD (1)  ·  Michael Graeber, M.D. (1)  ·  Ulrike Blume-Peytavi, MD (1)

Results publications

PMID 37838987, PMID 41286546